252 related articles for article (PubMed ID: 24519894)
1. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients.
Xue P; Kanai M; Mori Y; Nishimura T; Uza N; Kodama Y; Kawaguchi Y; Takaori K; Matsumoto S; Uemoto S; Chiba T
Cancer Med; 2014 Apr; 3(2):406-15. PubMed ID: 24519894
[TBL] [Abstract][Full Text] [Related]
2. Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy.
Huang PW; Chang CF; Hung CY; Hsueh SW; Chang PH; Yeh KY; Chen JS; Chen YY; Lu CH; Hung YS; Chou WC
Cancer Med; 2019 Sep; 8(12):5554-5563. PubMed ID: 31385456
[TBL] [Abstract][Full Text] [Related]
3. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy.
Xue P; Zhu L; Wan Z; Huang W; Li N; Chen D; Hu J; Yang H; Wang L
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1653-60. PubMed ID: 25792009
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment biomarkers as prognostic predictors of survival in patients with Pancreatic Cancer treated with Gemcitabine-based Therapy and 5-Fluorouracil: Neutrophil-to-lymphocyte ratio
Chen Y; Liao Y; Lam LM; He L; Tsang YS; Di YS; Liang ST; Xia Q
Int J Med Sci; 2020; 17(10):1449-1457. PubMed ID: 32624701
[TBL] [Abstract][Full Text] [Related]
5. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy.
Kou T; Kanai M; Yamamoto M; Xue P; Mori Y; Kudo Y; Kurita A; Uza N; Kodama Y; Asada M; Kawaguchi M; Masui T; Mizumoto M; Yazumi S; Matsumoto S; Takaori K; Morita S; Muto M; Uemoto S; Chiba T
Int J Clin Oncol; 2016 Feb; 21(1):118-25. PubMed ID: 26123314
[TBL] [Abstract][Full Text] [Related]
6. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
Maier-Stocker C; Bitzer M; Malek NP; Plentz RR
Scand J Gastroenterol; 2014 Dec; 49(12):1480-5. PubMed ID: 25390691
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (≥70 years of age): a retrospective cohort study at the National Center for Tumor Diseases Heidelberg.
Berger AK; Abel U; Komander C; Harig S; Jäger D; Springfeld C
Pancreatology; 2014; 14(3):211-5. PubMed ID: 24854617
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.
Formica V; Morelli C; Ferroni P; Nardecchia A; Tesauro M; Pellicori S; Cereda V; Russo A; Riondino S; Guadagni F; Roselli M
Cancer Biomark; 2016 Sep; 17(3):335-345. PubMed ID: 27434293
[TBL] [Abstract][Full Text] [Related]
10. The relation between inflammation-based parameters and survival in metastatic pancreatic cancer.
Turker S; Cilbir E; Guven DC; Karacin C; Yalcin S
J Cancer Res Ther; 2021; 17(2):510-515. PubMed ID: 34121700
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
Gutierrez-Sainz L; Viñal D; Villamayor J; Martinez-Perez D; Garcia-Cuesta JA; Ghanem I; Custodio A; Feliu J
Clin Transl Oncol; 2021 Sep; 23(9):1838-1846. PubMed ID: 33866520
[TBL] [Abstract][Full Text] [Related]
12. Comparative outcomes between initially unresectable and recurrent cases of advanced pancreatic cancer following palliative chemotherapy.
Xue P; Kanai M; Mori Y; Nishimura T; Uza N; Kodama Y; Kawaguchi Y; Takaori K; Matsumoto S; Uemoto S; Chiba T
Pancreas; 2014 Apr; 43(3):411-6. PubMed ID: 24622071
[TBL] [Abstract][Full Text] [Related]
13. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.
Lee Y; Kim SH; Han JY; Kim HT; Yun T; Lee JS
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2009-16. PubMed ID: 22772951
[TBL] [Abstract][Full Text] [Related]
14. The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.
Lee BM; Chung SY; Chang JS; Lee KJ; Seong J
Gut Liver; 2018 May; 12(3):342-352. PubMed ID: 29409306
[TBL] [Abstract][Full Text] [Related]
15. Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer.
Terao T; Kumagi T; Hyodo I; Yokota T; Azemoto N; Miyata H; Kuroda T; Ohno Y; Tanaka Y; Shibata N; Imamura Y; Kanemitsu K; Miyake T; Koizumi M; Hiasa Y;
Medicine (Baltimore); 2021 Oct; 100(43):e27591. PubMed ID: 34713835
[TBL] [Abstract][Full Text] [Related]
16. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma.
Chen Y; Yan H; Wang Y; Shi Y; Dai G
Sci Rep; 2017 Apr; 7(1):753. PubMed ID: 28392554
[TBL] [Abstract][Full Text] [Related]
17. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Cheng SH; Cheng YJ; Jin ZY; Xue HD
Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of neutrophil-to-lymphocyte ratio in advanced pancreatic ductal adenocarcinoma: impact of baseline fluctuation and changes during chemotherapy.
Teo M; Mohd Sharial MS; McDonnell F; Conlon KC; Ridgway PF; McDermott RS
Tumori; 2013; 99(4):516-22. PubMed ID: 24326841
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-lymphocyte ratio as a prognostic marker for chemotherapy in advanced lung cancer.
Liu ZL; Zeng TT; Zhou XJ; Ren YN; Zhang L; Zhang XX; Ding ZY
Int J Biol Markers; 2016 Dec; 31(4):e395-e401. PubMed ID: 27416842
[TBL] [Abstract][Full Text] [Related]
20. The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients.
Piciucchi M; Stigliano S; Archibugi L; Zerboni G; Signoretti M; Barucca V; Valente R; Fave GD; Capurso G
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
